1. Home
  2. INMD vs ANNX Comparison

INMD vs ANNX Comparison

Compare INMD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMode Ltd.

INMD

InMode Ltd.

N/A

Current Price

$13.11

Market Cap

842.0M

Sector

Health Care

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$5.94

Market Cap

730.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INMD
ANNX
Founded
2008
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.0M
730.4M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
INMD
ANNX
Price
$13.11
$5.94
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$16.75
$16.50
AVG Volume (30 Days)
870.5K
2.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.70
N/A
Revenue Next Year
$3.99
N/A
P/E Ratio
$10.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.95
$1.29
52 Week High
$19.09
$7.18

Technical Indicators

Market Signals
Indicator
INMD
ANNX
Relative Strength Index (RSI) 33.33 57.59
Support Level N/A $4.69
Resistance Level $14.80 $7.18
Average True Range (ATR) 0.28 0.33
MACD -0.09 0.10
Stochastic Oscillator 6.90 68.02

Price Performance

Historical Comparison
INMD
ANNX

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: